In advanced cancer treatment, combination chemotherapy remains a foundational therapeutic strategy. Dual-payload ADCs enable targeted chemotherapeutic combinations, offering enhanced efficacy and the potential to overcome drug resistance.
By integrating two distinct glycan-based conjugation technologies and optimizing payload combinations, we have developed stable dual-payload ADCs with DAR4 and DAR2 configurations. Furthermore, this glycan-based dual-payload platform can be combined with conventional thiol-based conjugation, significantly expanding the potential for novel conjugate drugs.
The representative candidate, JSKN021, has demonstrated high stability and favorable safety in preclinical studies, exhibiting superior inhibitory activity compared to competitive molecules across various animal tumor models with different cells. And we plan to submit an Investigational New Drug (IND) application shortly.
